This article is a correction to:
Therapeutic strategies targeting folate receptor α for ovarian cancer
Jia Mai
Limei Wu
Ling Yang1
Rutie Yin
Jinke Li
Qintong Li- 1Department of Laboratory Medicine, Obstetrics & Gynecology and Pediatrics, West China Second University Hospital, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Development and Related Diseases of Women and Children Key Laboratory of Sichuan Province, Center of Growth, Metabolism and Aging, State Key Laboratory of Biotherapy and Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu, Sichuan, China
- 2Department of Obstetrics and Gynecology, Chengdu Second People’s Hospital, Chengdu, Sichuan, China
- 3Department of Clinical Laboratory, The first Affiliated Hospital of Zhengzhou University, Zhengzhou, China
A Corrigendum on
Therapeutic strategies targeting folate receptor α for ovarian cancer
By Mai J, Wu L, Yang L, Sun T, Liu X, Yin R, Jiang Y, Li J and Li Q (2023). Front. Immunol. 14:1254532. doi: 10.3389/fimmu.2023.1254532
In the published article, there was an error in Figure 1 as published. PCTF is a symporter that transport H+ ion together with the folate transporter, we made a mistake with the direction of one arrow, by making it like PCFT is portrayed as an antiporter. The corrected Figure 1 and its caption appear below.
Figure 1
Figure 1 The three types of folate transporters. The uptake of extracellular folate is achieved mainly through three types of folate transporters. (1) RFC, an anion antiporter that uses a gradient of higher organic phosphate in the cell to transport folate into the cell while transporting organic phosphate out of the cell, (2) PCFT, a proton-coupled transporter, (3) folate receptor family (only FRα is shown). They transfer folate through endocytosis in selected tissues.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: ovarian cancer, folate receptor α, FOLR1, mirvetuximab soravtansine, MIRV, Elahere, antibody-drug conjugate, ADC
Citation: Mai J, Wu L, Yang L, Sun T, Liu X, Yin R, Jiang Y, Li J and Li Q (2024) Corrigendum: Therapeutic strategies targeting folate receptor α for ovarian cancer. Front. Immunol. 15:1403324. doi: 10.3389/fimmu.2024.1403324
Received: 19 March 2024; Accepted: 08 April 2024;
Published: 17 April 2024.
Edited and Reviewed by:
Nurit Hollander, Tel Aviv University, IsraelCopyright © 2024 Mai, Wu, Yang, Sun, Liu, Yin, Jiang, Li and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yongmei Jiang, amlhbmdfeW1Ac2N1LmVkdS5jbg==; Jinke Li, amlua2VsaUBzY3UuZWR1LmNu; Qintong Li, bGlxaW50b25nQHNjdS5lZHUuY24=